Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A 25-year evaluation of direct local international normalized ratio calibration of the Owren type prothrombin time method in Sweden.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Bariatric surgery improves fibrinolysis in individuals with obesity with and without concomitant type 2 diabetes.

Clinical nutrition (Edinburgh, Scotland)·2026
Same author

Confining thrombus morphospace through targeted inhibition of platelet mechanosensory signaling.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Evaluation of MRX PT DOAC as a new screening method for detecting interferences in thrombophilia analyses.

Scandinavian journal of clinical and laboratory investigation·2025
Same author

Alterations in platelet activity and endothelial glycocalyx biomarkers by treatment with an angiotensin converting enzyme inhibitor or an alpha-1 adrenoceptor antagonist in patients with hypertension: results from the DoRa study.

Platelets·2024
Same author

Exploring the morphine-platelet activity association in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Platelets·2024

Related Experiment Video

Updated: Jun 28, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Glycerol monooleate-blood interactions.

Emma M Ericsson1, Lars Faxälv, Anna Weissenrieder

  • 1Laboratory of Applied Physics, Department of Physics, Chemistry and Biology, Linköping University, SE-58183 Linköping, Sweden. emmer@ifm.liu.se

Colloids and Surfaces. B, Biointerfaces
|November 11, 2008
PubMed
Summary

Glycerol monooleate (GMO) coatings show weak blood activation and minimal hemolysis. Despite some detachment, GMO surfaces prolonged coagulation time, suggesting potential biomaterial applications.

More Related Videos

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Related Experiment Videos

Last Updated: Jun 28, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Area of Science:

  • Biomaterials Science
  • Surface Chemistry
  • Hemocompatibility Studies

Background:

  • Assessing the blood compatibility of novel biomaterials is crucial for medical applications.
  • Glycerol monooleate (GMO) is a lipid with potential for surface modification.
  • Understanding GMO's interaction with blood proteins and cellular components is necessary.

Purpose of the Study:

  • To evaluate the initial blood compatibility of glycerol monooleate (GMO)-coated surfaces.
  • To investigate the stability and properties of GMO coatings on protein-premodified silica surfaces.
  • To determine GMO's potential as a biomaterial, biosealant, or in colloidal dispersions.

Main Methods:

  • Protein immobilization (fibrinogen, HSA) on silica surfaces.
  • Dip-coating with GMO in ethanol.
  • Characterization using ellipsometry, SEM, and coagulation imaging.
  • Hemolysis tests and whole blood coagulation time measurements via rheometry.

Main Results:

  • GMO coatings achieved a thickness of ~350 A but showed significant detachment in aqueous and shear conditions.
  • A thinner, stable GMO layer (50-70 A) remained on protein-coated surfaces.
  • GMO significantly prolonged coagulation time compared to HSA-coated surfaces and exhibited weak hemolytic activity.

Conclusions:

  • GMO exhibits weak blood activation and low hemolytic potential.
  • The detachment behavior suggests potential for self-assembly in biological fluids.
  • GMO may be suitable for specific biomaterial applications like biosealants or colloidal systems.